CANbridge Pharmaceuticals Inc. (01228) released its Monthly Return for November 2025, reporting no changes to overall share capital. The authorized share capital remains at 5,000,000,000 ordinary shares with a par value of USD 0.00001 each, totaling USD 50,000.

The total number of issued shares stands unchanged at 510,826,484. During the month, 60,000 share options under the Post-IPO Share Option Scheme lapsed, leaving 8,548,750 options outstanding. No new shares were issued, and no treasury shares were transferred or cancelled. The company received no proceeds from the exercise of share options.

Under the Pre-IPO Equity Incentive Plan, 21,858,960 shares remain available for future issuance, while the Post-IPO RSU Scheme shows no shares available. The confirmation was submitted by Chairman, Dr. James Qun Xue, on December 4, 2025.